YmAbs Therapeutics (YMAB)
(Delayed Data from NSDQ)
$12.37 USD
-0.44 (-3.43%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $12.37 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Y-mAbs Therapeutics, Inc. [YMAB]
Reports for Purchase
Showing records 121 - 140 ( 151 total )
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Omburtamab Approval Pathway Finalized With FDA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Priority Review Voucher Sale an Incremental Positive; Reiterate Buy; Raising PT to $41
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Y-mAbs Could Score a Priority Review Voucher Hat Trick; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways and Perspectives From R-D Day Event; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Naxitamab Looks Nice in Frontline Neuroblastoma; R-D Day Review
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Rolling Naxitamab Biologics License Application Filing Starts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Omburtamab DSRCT Data Presented; 3Q19 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SIOP Presentations Further Reinforce Naxitamab and Omburtamab Efficacy Profiles.
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Duo to Dominate Pediatric Cancers, Naxi - Ombur Suit up for Near-Term BLAs
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D